+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Cervical Cancer Screening Market Report, Forecast by Europe Cervical Cancer Test, Market, Countries and Company Analysis, 2024-2032

  • PDF Icon

    Report

  • 220 Pages
  • August 2024
  • Region: Europe
  • Renub Research
  • ID: 5562700
The Europe Cervical Cancer Screening Market was valued at US$ 9.42 Billion in 2023 and will reach US$ 14.63 Billion by 2032, with a CAGR of 5.01% from 2024 to 2032. The rise in female elderly population, rising cervical cancer prevalence, and improvements in cervical cancer screening are driving growth in the cervical cancer screening market. In addition, advantageous health reimbursement, proactive government assistance, and growing awareness of women's health are a few of the key elements anticipated to boost the cervical cancer screening market in Europe.

Europe Cervical Cancer Screening Market Overview

One type of cancer brought on by unchecked cell proliferation is cervical cancer. A cervix infection with the human papillomavirus (HPV) is linked to an increased risk of cervical cancer. Cervical cancer is the second greatest cause of cancer-related mortality for women between the ages of 15 and 44 in Europe and the ninth most common type of cancer that affects women overall. In the nations that make up the European Union, cervical cancer affects over 100,000 women annually. This disease is a key measure of how well healthcare systems handle cancer. The effectiveness of treatment and early identification both affect the survival rates for cervical cancer. Fortunately, if precancerous cells are found and treated before they spread, cervical cancer can be generally avoided. Since more than 90% of cases of cervical cancer are caused by the human papillomavirus (HPV), vaccination against the main HPV types linked to the disease is essential to lowering its incidence.

Growth Factors in the Cervical Cancer Screening Industry

Technological Developments

As screening technologies continue to progress, the market for cervical cancer screening is expected to rise significantly. Advances like HPV DNA testing, automated screening devices, and liquid-based cytology improve the precision, efficacy, and accessibility of cervical cancer screening initiatives. The incidence and fatality rates of cervical cancer are decreased by the early diagnosis of precancerous lesions and HPV infections made possible by these technical developments. In order to enhance screening procedures and broaden the scope of screening, manufacturers consistently allocate resources to research and development. This helps to propel the market forward and empower women's health.

Artificial Intelligence (AI) and Digital Health Solutions Integration

Cervical cancer screening procedures are revolutionized by the integration of artificial intelligence (AI) and digital health technologies, which present chances to enhance patient care, accuracy, and efficiency. Artificial intelligence (AI) systems examine cervical pictures, Pap smear results, and HPV test data to help medical professionals interpret screening results, minimize diagnostic errors, and improve patient management techniques. Digital health platforms improve the accessibility and continuity of care for women in underserved or distant locations by facilitating centralized data administration, telemedicine consultations, and remote screening. In addition to facilitating the delivery of tailored and precision medicine techniques in cervical cancer screening and management, the adoption of AI and digital health solutions promotes market growth.

Germany Cervical Cancer Screening Market Overview:

Within the healthcare sector, Germany's cervical cancer screening market is a sizable and expanding business. Germany's strong healthcare system, which prioritizes early identification and preventive care, is the market's main driver. Regular screening programs, backed by insurance coverage and public health campaigns, are widely implemented. These programs include Pap smears and HPV (human papillomavirus) testing.

Germany's market benefits from state-of-the-art facilities for healthcare and modern technology. Molecular diagnostics and liquid-based cytology are two examples of screening technology innovations that are improving detection rates and accuracy. Moreover, rising screening rates are a result of growing knowledge about cervical cancer and the efficacy of vaccinations.

The market is growing because of government regulations and recommendations, such as the inclusion of HPV vaccination in national immunization regimens. The need for more accurate and effective screening techniques is also being driven by the nation's emphasis on early intervention and individualized medicine.

Effective management and prevention of cervical cancer are ensured by robust public health initiatives, cutting-edge technology, and a supportive policy environment, which collectively define Germany's cervical cancer screening industry.

Europe Cervical Cancer Screening Market Company Overview

Some of the industry leaders seen in the Europe Cervical Cancer Screening Market Includes Abbott laboratories, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, Cardinal Health.

Europe Cervical Cancer Screening Market News

  • In June 2022, an official 'human papillomavirus (HPV) self-sampling solution' launch has been announced in the regions accepting the CE mark by the international healthcare corporation based in Switzerland, F. Hoffmann-La Roche Ltd. The primary use of this test kit is for HPV screening, which identifies women who may be at risk of cervical cancer.
  • In March 2021, GynTect is an advanced cervical cancer test. Oncgnostics GmbH, a leading producer of cancer-related in-vitro diagnostic tests, and EUROIMMUN, a well-known supplier of immunodiagnostic laboratory solutions, announced a strategic partnership to commercialize this test. Under the terms of the partnership, EUROIMMUN would sell GynTect throughout Europe, notably in Turkey, Italy, Portugal, and Poland.

Europe Cervical Cancer Test (Screening) - Market breakup in 2 viewpoints:

  • Pap Smear Test Market
  • HPV DNA Test Market

Counties - covered in 2 viewpoints:

  • Pap Smear Market
  • HPV DNA Market
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • Sweden
  • Switzerland
  • Norway
  • Netherlands

The key players have been covered from 4 viewpoints:

  • Overviews
  • Recent Developments & Strategies
  • Product Portfolio & Product Launch in Last 1 Year
  • Revenue

Company Analysis:

  • Abbott laboratories
  • Hologic Corporation
  • Becton
  • Siemens AG
  • Roche Diagnostics
  • Quest Diagnostics
  • Cardinal Health

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Europe Cervical Cancer Screening Analysis
5.1 Europe Cervical Cancer Market
5.2 Europe Cervical Cancer Population
6. Europe Cervical Cancer Test (Screening) Analysis
6.1 Europe Cervical Cancer Test Population
6.1.1 Pap smear Test Population
6.1.2 HPV DNA Test Population
6.2 Europe Cervical Cancer Test (Screening) Market
6.2.1 Pap Smear Test Market
6.2.2 HPV DNA Test Market
7. By Countries - Europe Cervical Cancer Test Market & Population Share Analysis
7.1 Europe Cervical Cancer Test Population Share
7.1.1 Pap Smear Population
7.1.2 HPV DNA Population
7.2 Europe Cervical Cancer Market Share
7.2.1 Pap Smear Market
7.2.2 HPV DNA Market
8. United Kingdom - Cervical Cancer Test Analysis
8.1 Population - Cervical Cancer Test (Screening)
8.1.1 Pap smear Test Population
8.1.2 HPV DNA Test Population
8.2 Market - Cervical Cancer Test (Screening)
8.2.1 Pap smear Test Market
8.2.2 HPV DNA Test Market
9. France - Cervical Cancer Test Analysis
9.1 Population - Cervical Cancer Test (Screening)
9.1.1 Pap smear Test Population
9.1.2 HPV DNA Test Population
9.2 Market - Cervical Cancer Test (Screening)
9.2.1 Pap Smear Test Market
9.2.2 HPV DNA Test Market
10. Germany - Cervical Cancer Test Analysis
10.1 Population - Cervical Cancer Test (Screening)
10.1.1 Pap smear Test Population
10.1.2 HPV DNA Test Population
10.2 Market - Cervical Cancer Test (Screening)
10.2.1 Pap Smear Test Market
10.2.2 HPV DNA Test Market
11. Italy - Cervical Cancer Test Analysis
11.1 Population - Cervical Cancer Test (Screening)
11.1.1 Pap smear Test Population
11.1.2 HPV DNA Test Population
11.2 Market - Cervical Cancer Test (Screening)
11.2.1 Pap Smear Test Market
11.2.2 HPV DNA Test Market
12. Spain - Cervical Cancer Test Analysis
12.1 Population - Cervical Cancer Test (Screening)
12.1.1 Pap smear Test Population
12.1.2 HPV DNA Test Population
12.2 Market - Cervical Cancer Test (Screening)
12.2.1 Pap Smear Test Market
12.2.2 HPV DNA Test Market
13. Sweden - Cervical Cancer Test Analysis
13.1 Population - Cervical Cancer Test (Screening)
13.1.1 Pap smear Test Population
13.1.2 HPV DNA Test Population
13.2 Market - Cervical Cancer Test (Screening)
13.2.1 Pap Smear Test Market
13.2.2 HPV DNA Test Market
14. Switzerland - Cervical Cancer Test Analysis
14.1 Population - Cervical Cancer Test (Screening)
14.1.1 Pap smear Test Population
14.1.2 HPV DNA Test Population
14.2 Market - Cervical Cancer Test (Screening)
14.2.1 Pap Smear Test Market
14.2.2 HPV DNA Test Market
15. Norway - Cervical Cancer Test Analysis
15.1 Population - Cervical Cancer Test (Screening)
15.1.1 Pap smear Test Population
15.1.2 HPV DNA Test Population
15.2 Market - Cervical Cancer Test (Screening)
15.2.1 Pap Smear Test Market
15.2.2 HPV DNA Test Market
16. Netherlands - Cervical Cancer Test Analysis
16.1 Population - Cervical Cancer Test (Screening)
16.1.1 Pap smear Test Population
16.1.2 HPV DNA Test Population
16.2 Market - Cervical Cancer Test (Screening)
16.2.1 Pap Smear Test Market
16.2.2 HPV DNA Test Market
17. Porter’s Five Forces
17.1 Bargaining Power of Buyer
17.2 Bargaining Power of Supplier
17.3 Threat of New Entrants
17.4 Rivalry among Existing Competitors
17.5 Threat of Substitute Products
18. SWOT Analysis
18.1 Strengths
18.2 Weaknesses
18.3 Opportunities
18.4 Threats
19. Company Analysis
19.1 Abbott laboratories
19.1.1 Overviews
19.1.2 Recent Developments & Strategies
19.1.3 Product Portfolio & Product Launch in Last 1 Year
19.1.4 Revenue
19.2 Hologic Corporation
19.2.1 Overviews
19.2.2 Recent Developments & Strategies
19.2.3 Product Portfolio & Product Launch in Last 1 Year
19.2.4 Revenue
19.3 Becton
19.3.1 Overviews
19.3.2 Recent Developments & Strategies
19.3.3 Product Portfolio & Product Launch in Last 1 Year
19.3.4 Revenue
19.4 Siemens AG
19.4.1 Overviews
19.4.2 Recent Developments & Strategies
19.4.3 Product Portfolio & Product Launch in Last 1 Year
19.4.4 Revenue
19.5 Roche Diagnostics
19.5.1 Overviews
19.5.2 Recent Developments & Strategies
19.5.3 Product Portfolio & Product Launch in Last 1 Year
19.5.4 Revenue
19.6 Quest Diagnostics
19.6.1 Overviews
19.6.2 Recent Developments & Strategies
19.6.3 Product Portfolio & Product Launch in Last 1 Year
19.6.4 Revenue
19.7 Cardinal Health
19.7.1 Overviews
19.7.2 Recent Developments & Strategies
19.7.3 Product Portfolio & Product Launch in Last 1 Year
19.7.4 Revenue

Companies Mentioned

  • Abbott laboratories
  • Hologic Corporation
  • Becton
  • Siemens AG
  • Roche Diagnostics
  • Quest Diagnostics
  • Cardinal Health

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information